NASDAQ:IMGN ImmunoGen - IMGN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.81 +0.02 (+0.53%) (As of 03/27/2023 05:42 PM ET) Add Compare Share Share Today's Range$3.74▼$3.8750-Day Range$3.67▼$4.9252-Week Range$3.10▼$6.63Volume1.95 million shsAverage Volume3.48 million shsMarket Capitalization$861.24 millionP/E RatioN/ADividend YieldN/APrice Target$13.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ImmunoGen MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside250.0% Upside$13.33 Price TargetShort InterestBearish11.06% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.71Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.80) to ($0.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector409th out of 995 stocksPharmaceutical Preparations Industry188th out of 482 stocks 3.4 Analyst's Opinion Consensus RatingImmunoGen has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.33, ImmunoGen has a forecasted upside of 250.0% from its current price of $3.81.Amount of Analyst CoverageImmunoGen has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.06% of the outstanding shares of ImmunoGen have been sold short.Short Interest Ratio / Days to CoverImmunoGen has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in ImmunoGen has recently increased by 9.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunoGen does not currently pay a dividend.Dividend GrowthImmunoGen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreImmunoGen has received a 73.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for ImmunoGen is -0.85. Previous Next 3.2 News and Social Media Coverage News SentimentImmunoGen has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for ImmunoGen this week, compared to 2 articles on an average week.Search Interest42 people have searched for IMGN on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.MarketBeat Follows4 people have added ImmunoGen to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.34% of the stock of ImmunoGen is held by insiders.Percentage Held by Institutions89.13% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ImmunoGen are expected to grow in the coming year, from ($0.80) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoGen is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoGen is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoGen has a P/B Ratio of 5.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ImmunoGen (NASDAQ:IMGN) StockImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.Read More Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address IMGN Stock News HeadlinesMarch 25, 2023 | finance.yahoo.comImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual MeetingMarch 21, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for ImmunoGen, Inc. Boosted by Analyst (NASDAQ:IMGN)March 27, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 3, 2023 | finance.yahoo.comImmunoGen, Inc. (NASDAQ:IMGN) Q4 2022 Earnings Call TranscriptMarch 1, 2023 | finance.yahoo.comImmunoGen Allows Vertex Pharma Use Its Technology For Conditioning Agents For Use With Gene EditingFebruary 16, 2023 | finance.yahoo.comWith 72% institutional ownership, ImmunoGen, Inc. (NASDAQ:IMGN) is a favorite amongst the big gunsJanuary 3, 2023 | finance.yahoo.comNeed To Know: The Consensus Just Cut Its ImmunoGen, Inc. (NASDAQ:IMGN) Estimates For 2023December 30, 2022 | finance.yahoo.comCompany News for Dec 30, 2022March 27, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.December 28, 2022 | finance.yahoo.comImmunoGen's Newly Approved Ovarian Cancer Drug Listed As Preferred RegimeDecember 27, 2022 | finance.yahoo.comImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 15, 2022 | finance.yahoo.comWill ImmunoGen (NASDAQ:IMGN) Spend Its Cash Wisely?December 10, 2022 | finance.yahoo.comImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASHNovember 17, 2022 | finance.yahoo.comIndustry Analysts Just Upgraded Their ImmunoGen, Inc. (NASDAQ:IMGN) Revenue Forecasts By 23%November 16, 2022 | finance.yahoo.comAfter FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This AnalystNovember 15, 2022 | finance.yahoo.comImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer DrugNovember 15, 2022 | finance.yahoo.comFDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian CancerNovember 9, 2022 | finance.yahoo.comImmunoGen Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 8, 2022 | finance.yahoo.comImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View UpNovember 3, 2022 | finance.yahoo.comShould You Buy ImmunoGen (IMGN) Ahead of Earnings?October 28, 2022 | finance.yahoo.comImmunoGen (IMGN) Expected to Beat Earnings Estimates: Should You Buy?October 14, 2022 | bizjournals.comForm D Friday: CXL Ophthalmics $32M, i2o Therapeutics $33.5M, Phoenicis Therapeutics $9.9M - The Business JournalsOctober 13, 2022 | finance.yahoo.comINOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis - Yahoo FinanceOctober 5, 2022 | businesswire.comGlobal Drug Conjugates Market Report (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com - Business WireOctober 4, 2022 | nasdaq.comImmunoGen (IMGN) Shares Cross Above 200 DMA - NasdaqSeptember 29, 2022 | businesswire.comImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS - Business WireSeptember 23, 2022 | reuters.comIMGN.OQ - ImmunoGen, Inc. | Stock Price & Latest News | ReutersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address IMGN Company Calendar Last Earnings3/01/2023Today3/27/2023Next Earnings (Estimated)5/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IMGN CUSIP45253H10 CIK855654 Webwww.immunogen.com Phone(781) 895-0600Fax781-895-0611Employees106Year Founded1981Price Target and Rating Average Stock Price Forecast$13.33 High Stock Price Forecast$22.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+250.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-222,930,000.00 Net Margins-204.93% Pretax Margin-203.81% Return on Equity-100.18% Return on Assets-55.33% Debt Debt-to-Equity RatioN/A Current Ratio2.50 Quick Ratio2.50 Sales & Book Value Annual Sales$108.78 million Price / Sales7.92 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book5.37Miscellaneous Outstanding Shares226,046,000Free Float218,496,000Market Cap$861.24 million OptionableOptionable Beta0.94 Social Links Key ExecutivesMark Joseph EnyedyPresident, Chief Executive Officer & DirectorRenee LentiniVP-Finance, Chief Financial & Accounting OfficerAnna BerkenblitChief Medical Officer & Senior Vice PresidentMichael J. VasconcellesEVP-Research, Development & Medical AffairsStacy A. CoenChief Business Officer & Senior Vice PresidentKey CompetitorsGeronNASDAQ:GERNInnovivaNASDAQ:INVAOPKO HealthNASDAQ:OPKMannKindNASDAQ:MNKDIntercept PharmaceuticalsNASDAQ:ICPTView All CompetitorsInstitutional OwnershipVoya Investment Management LLCSold 304,318 shares on 2/28/2023Ownership: 0.330%Teachers Retirement System of The State of KentuckyBought 15,570 shares on 2/22/2023Ownership: 0.078%Alliancebernstein L.P.Sold 35,409 shares on 2/16/2023Ownership: 0.131%HealthCor Management L.P.Sold 1,150,000 shares on 2/16/2023Ownership: 0.068%E Fund Management Co. Ltd.Bought 6,577 shares on 2/15/2023Ownership: 0.032%View All Institutional Transactions IMGN Stock - Frequently Asked Questions Should I buy or sell ImmunoGen stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMGN shares. View IMGN analyst ratings or view top-rated stocks. What is ImmunoGen's stock price forecast for 2023? 4 analysts have issued 12-month target prices for ImmunoGen's shares. Their IMGN share price forecasts range from $9.00 to $22.00. On average, they predict the company's stock price to reach $13.33 in the next year. This suggests a possible upside of 250.0% from the stock's current price. View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts. How have IMGN shares performed in 2023? ImmunoGen's stock was trading at $4.96 at the start of the year. Since then, IMGN shares have decreased by 23.2% and is now trading at $3.81. View the best growth stocks for 2023 here. Are investors shorting ImmunoGen? ImmunoGen saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 25,000,000 shares, an increase of 9.6% from the February 28th total of 22,800,000 shares. Based on an average daily trading volume, of 3,470,000 shares, the days-to-cover ratio is presently 7.2 days. View ImmunoGen's Short Interest. When is ImmunoGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. View our IMGN earnings forecast. How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) issued its earnings results on Wednesday, March, 1st. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.06. The biotechnology company had revenue of $41.17 million for the quarter, compared to analyst estimates of $17.18 million. ImmunoGen had a negative trailing twelve-month return on equity of 100.18% and a negative net margin of 204.93%. The firm's revenue for the quarter was up 47.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.17) earnings per share. What ETFs hold ImmunoGen's stock? ETFs with the largest weight of ImmunoGen (NASDAQ:IMGN) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ). What guidance has ImmunoGen issued on next quarter's earnings? ImmunoGen updated its FY 2023 earnings guidance on Wednesday, March, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $30.00 million-$35.00 million, compared to the consensus revenue estimate of $117.67 million. What is Mark J. Enyedy's approval rating as ImmunoGen's CEO? 16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees. What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX). What is ImmunoGen's stock symbol? ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN." Who are ImmunoGen's major shareholders? ImmunoGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (9.90%), Jennison Associates LLC (4.14%), Maverick Capital Ltd. (3.12%), Morgan Stanley (1.93%), Geode Capital Management LLC (1.74%) and Braidwell LP (1.57%). View institutional ownership trends. How do I buy shares of ImmunoGen? Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ImmunoGen's stock price today? One share of IMGN stock can currently be purchased for approximately $3.81. How much money does ImmunoGen make? ImmunoGen (NASDAQ:IMGN) has a market capitalization of $861.24 million and generates $108.78 million in revenue each year. The biotechnology company earns $-222,930,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. How many employees does ImmunoGen have? The company employs 106 workers across the globe. Does ImmunoGen have any subsidiaries? The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..Read More How can I contact ImmunoGen? ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611. This page (NASDAQ:IMGN) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.